Abstract
Bayesian statistics have the advantage of being easily established and derived. Thus, we will use this approach to find the distribution of the predictive probabilities of the data not observed yet in the conception of clinical trials phase II. Such perspectives are necessary in cases or in reason treat ethical preoccupations or ether to achieve trials which are particularly toxic or expensive. We propose, in reason of neutrality, to calculate the predictive probabilities within a Bayesian case, where the prior is non informative in different models apply in clinical trials.
References
Chow, S. C., 2005. Statistical consideration of adaptive methods in clinical development. Journal Biopharm Stat, 15, 575-91.
Chow, S. C. and al., 2011. Bayesian adaptive methods for clinical trials. Chapman &Hall/CRC Press, New York. ISBN: 978-1-4398-2548-8.
Chow, S. C. and al., 2012. On the independence of data monitoring committee in adaptive design clinical trials. Journal of biopharmaceutical statistics; 22(4):853-867.
Chow, S. C. and Chang M., 2007. Adaptive design in clinical trials. Chapman & Hall/CRC. Biostatistics Series, USA. ISBN: 1-58488-776-1.
Guosheng, Y. and al., 2012. Phase II trial design with Bayesian adaptive randomization and predictive probability. Royal statistical society: Series C (Applied statistics), 61, 219-235.
Hoff, P.D., 2009. A first course in Bayesian statistical Methods. Springer science + Business media, New York. ISBN: 978-0-387-92299-7.
Lee, J.J. and Liu, D.D., 2008. A predictive probability design for phase II cancer clinical trials. Clinical trials; 5:93-106.
Merabet, H., 2004. Index and prevision of satisfaction in exponential models for clinical trials. Statistica, anno LXIV, n3, 441-453
Robert, C.P., 2006. Le choix Bayesien; principe et pratique. Springer-Verlag France, Paris. ISBN: 978-2-287-25173-3.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2022 Journal of Sciences & Technology